Toleranzia
0.522 SEK +0.77%Be the first to follow this company
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
TOL
Daily low / high price
0.518 / 0.522
SEK
Market cap
102.87M SEK
Turnover
24.16K SEK
Volume
46K
Financial calendar
Interim report
20.05.2024
General meeting
19.06.2024
Interim report
23.08.2024
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 57.1 % | 57.1 % |
Avanza Pension | 3.5 % | 3.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Correction: Toleranzia AB receives loan commitment of SEK 20 million
Toleranzia AB receives loan commitment of SEK 20 million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools